Optogenetics: using light to switch nerve cells on and off

Optogenetics is a research method that uses light to control specific nerve cells. Scientists add a light-sensitive protein to chosen cells, then shine light on them to switch their electrical activity on or off. It matters because it lets researchers test how particular cell types contribute to behaviour, and it has now reached a first, very early stage of testing in people, in the eye. Al Jazeera reports that on 5 October 2026 the Nobel Prize in Physiology or Medicine was announced for this work, shared by Karl Deisseroth of Stanford University, Peter Hegemann of Humboldt University of Berlin and Georg Nagel of the University of Würzburg, "for their discovery of a molecular switch for nerve cells" (Al Jazeera).

Optogenetics is, first and foremost, a research tool. Its use in people is at an early stage. This article is general information, not medical advice.

How it works

Some algae carry light-sensitive proteins that open tiny channels for ions when light hits them. The gene for one of these, channelrhodopsin-2 (ChR2), can be copied into nerve cells so that they gain the same sensitivity. In 2005 Boyden and colleagues reported that this gave millisecond-precise control of spiking and of synaptic transmission in mammalian neurons, with the gene delivered by lentiviral vectors (Boyden et al., 2005).

Light-driven pumps work in the other direction. In 2007 Zhang and colleagues described NpHR, a light-driven chloride pump from an archaeon, which can block neural activity. Because ChR2 and NpHR respond to well-separated colours of light, they can be used together to excite or silence cells. The same paper reports that together they control movement in the nematode worm C. elegans (Zhang et al., 2007).

What has been shown in the laboratory

The core biology is established in peer-reviewed papers from 2005 and 2007. Those studies were carried out in mammalian neurons, in worms and in mammalian brain tissue. They show that the method can control cells with fine timing and in a chosen cell type. They do not show that the method is safe or useful in people.

What has been shown in people so far

The only human efficacy evidence among the sources used here is a single case report from 2021. A patient with retinitis pigmentosa, an inherited retinal condition, could not detect objects. The patient received an injection into one eye of an adeno-associated viral vector carrying ChrimsonR, a light-gated channel, and wore goggles that projected light pulses onto the retina. With the goggles on, the patient could perceive, locate, count and touch objects using that eye alone. Without the goggles, or before treatment, the patient could not detect objects. The authors describe it as the first reported partial functional recovery in a neurodegenerative disease after optogenetic therapy (Sahel et al., 2021). The paper's abstract does not report how long the patient was followed or whether any side effects occurred.

A registered trial, NCT03326336, is testing a treatment called GS030 in retinitis pigmentosa. GS030 combines a gene therapy carrying ChrimsonR, given as a single injection into the eye, with repeated light stimulation from stimulating glasses. It is a Phase 1/2a, open-label, non-randomised, dose-escalation study sponsored by GenSight Biologics. As of its last update, posted on 2 March 2026, the registry record lists 10 enrolled participants, a status of active and not recruiting, a start date of 26 September 2018, and a primary outcome of safety and tolerability, measured by adverse events, at week 52. The estimated primary completion date is 26 October 2027 (ClinicalTrials.gov record). The trial's stated aim is to test safety and tolerability at rising doses. With no control group, it is not designed to show whether the treatment works better than no treatment.

What is reported but not yet established

The 2026 Nobel Prize is a recognition of the research, not evidence that any treatment is ready. The same press coverage also says that researchers hope optogenetics could improve cochlear implants, allowing more precise stimulation of the auditory nerve (Al Jazeera). That is a hope, not a result.

What is speculative

Ideas beyond the retina, including hearing, remain untested in people. Any such use would need its own trials, and none of the sources used here report one.

Limits and open problems

• Gene delivery. The light-sensitive gene has to reach the target cells, and the 2021 case used a viral vector injected into the eye. The sources used here do not report long-term safety data on expressing these foreign proteins in human cells.
• Light delivery. The patient needed goggles to project light onto the retina. The sources used here do not address how light would reach cells deep in the brain.
• Sample size. Human efficacy evidence rests on one patient. The GS030 trial (NCT03326336) is open-label and has 10 enrolled participants, with no randomised comparison.
• Animal to human gap. The foundational work used mammalian neurons, worms and brain tissue. Among the sources used here, the eye is the only site tested in people.

What to watch next

• Results from the GS030 trial (NCT03326336), including whether the registry record is updated with outcome data before its estimated completion in October 2027.
• Longer follow-up of the 2021 patient, and whether the authors or others publish adverse event data.
• Whether researchers report a way to deliver light safely to deeper brain tissue, which any use in the human brain would need.
• Any formal trials of optogenetics in hearing, which would test the cochlear idea reported in the press coverage.